Journal of hepato-biliary-pancreatic sciences · 2026
Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S-1, Irinotecan, and Oxaliplatin as Second-Line Chemotherapy After Gemcitabine Plus Nab-Paclitaxel for Unresectable Pancreatic Cancer.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Itonaga Masahiro, Ashida Reiko, Tamura Takashi, Yamashita Yasunobu, Kawaji Yuki, Shishimoto Takahiro, Morishita Hiromu, Hanada Keisuke, Kojima Fumiyoshi, Kitano Masayuki
Аннотация
OBJECTIVES: The optimal second-line chemotherapy after gemcitabine plus nab-paclitaxel (GnP) for unresectable pancreatic cancer (PC) remains unclear. This study compared the efficacy and safety of nanoliposomal irinotecan plus fluorouracil/leucovorin (NFF) and S-1, irinotecan, and oxaliplatin (S-IROX) after GnP failure.
METHODS: This single-center retrospective cohort study included patients with unresectable PC refractory to GnP who received NFF or S-IROX between July 2020 and June 2024. Progression-free survival (PFS), overall survival (OS), tumor response, and adverse events were evaluated. Prognostic factors were also assessed with subgroup analyses.
RESULTS: Seventy-nine patients were analyzed (NFF, n = 55; S-IROX, n = 24). Median PFS was significantly longer with S-IROX than with NFF (6.29 vs. 3.45 months; p = 0.048), and the overall response rate was higher (29% vs. 9%; p = 0.038). Median OS did not differ significantly (12.81 vs. 10.64 months; p = 0.170). The incidence of grade ≥ 3 adverse events was comparable. Multivariate analysis identified S-IROX, modified Glasgow Prognostic Score (mGPS) 0, and CA19-9 < 373 IU/L as independent predictors of longer PFS, while mGPS 0 and CA19-9 < 373 IU/L were associated with longer OS. Subgroup analyses showed favorable outcomes with S-IROX in locally advanced disease.
CONCLUSIONS: S-IROX may be an effective and safe second-line option after GnP, particularly for locally advanced PC.
METHODS: This single-center retrospective cohort study included patients with unresectable PC refractory to GnP who received NFF or S-IROX between July 2020 and June 2024. Progression-free survival (PFS), overall survival (OS), tumor response, and adverse events were evaluated. Prognostic factors were also assessed with subgroup analyses.
RESULTS: Seventy-nine patients were analyzed (NFF, n = 55; S-IROX, n = 24). Median PFS was significantly longer with S-IROX than with NFF (6.29 vs. 3.45 months; p = 0.048), and the overall response rate was higher (29% vs. 9%; p = 0.038). Median OS did not differ significantly (12.81 vs. 10.64 months; p = 0.170). The incidence of grade ≥ 3 adverse events was comparable. Multivariate analysis identified S-IROX, modified Glasgow Prognostic Score (mGPS) 0, and CA19-9 < 373 IU/L as independent predictors of longer PFS, while mGPS 0 and CA19-9 < 373 IU/L were associated with longer OS. Subgroup analyses showed favorable outcomes with S-IROX in locally advanced disease.
CONCLUSIONS: S-IROX may be an effective and safe second-line option after GnP, particularly for locally advanced PC.